

UPDATE – Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia



Dean Elterman¹, Mélanie Aubé-Peterkin², Howard Evans³, Hazem Elmansy⁴, Malek Meskawi⁵, Kevin C. Zorn⁵, Naeem Bhojani⁵

¹Division of Urology, University of Toronto, Toronto, ON, Canada; ²Division of Urology, McGill University, Montreal, QC, Canada; ³Division of Urology, University of Alberta, Edmonton, AB, Canada; ⁴Division of Urology, Northern Ontario School of Medicine, Thunder Bay, ON, Canada; ⁵Division of Urology, Université de Montréal, Montreal, QC, Canada

Cite as: Elterman D, Aubé-Peterkin M, Evans H, et al. UPDATE – Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia. *Can Urol Assoc J* 2022;16(8):245-56. <http://dx.doi.org/10.5489/auaj.7906>

Published online April 11, 2022

Introduction

The current document summarizes the state-of-the-art knowledge as it relates to management of male lower urinary tract symptoms (MLUTS) secondary to benign prostatic hyperplasia (BPH) by updating the 2018 Canadian Urological Association (CUA) BPH guideline.¹ The process continues to highlight the essential diagnostic and therapeutic information in a Canadian context. The information included in this document includes that reviewed for the 2010 guideline and further information obtained from an updated MEDLINE search of the English-language literature (search terms included BPH, alpha-blockers, 5-alpha reductase inhibitor, anti-cholinergic, beta3 agonist, phosphodiesterase type 5 inhibitor [PDE5I], transurethral resection of the prostate [TURP], monopolar, bipolar, open simple prostatectomy, enucleation, GreenLight, photoselective vaporization of the prostate [PVP], Aquablation, Rezum, UroLift, temporarily implanted nitinol device [iTIND]), as well as review of the most recent American Urological Association (AUA)² and European Association of Urology (EAU) guidelines.³ References include those of historical importance, but management recommendations are based on literature published between 2000 and 2021. When information and data is available from multiple sources, the most relevant (usually most recent) article is cited based on committee opinion.

These guidelines are directed toward the typical male patient over 50 years of age presenting with LUTS and benign prostatic enlargement (BPE) and/or benign prostatic obstruction (BPO). It is recognized that men with LUTS associated

with causes other than BPO may require more extensive diagnostic workup and different treatment considerations. We acknowledge that not all patients identify as male. These guidelines should also be applicable to non-binary people, transwomen, and any patients who may have anatomical features of a cis-male genitourinary tract, such as a prostate. It is our intent to make these guidelines inclusive to all persons experiencing LUTS or an enlarged prostate.

In this document, we will address both diagnostic and treatment issues. Diagnostic guidelines are described in the following terms as: mandatory, recommended, optional, or not recommended. The recommendations for diagnostic guidelines and principles of treatment were developed on the basis of clinical principle (widely agreed upon by Canadian urologists) and/or expert opinion (consensus of committee and reviewers). The grade of recommendation will not be offered for diagnostic recommendations. Guidelines for treatment are described using the GRADE approach⁴ for summarizing the evidence and making recommendations.

1. Diagnostic guidelines

The committee recommended minor revisions in regard to diagnostic considerations as outlined in the 2018 CUA BPH guideline.¹

1.1. Mandatory

Mandatory evaluations include:

- History
- Physical examination, including DRE
- Urinalysis

In the initial evaluation of a man presenting with LUTS, the evaluation of symptom severity and bother is essential. Medical history should include relevant prior and current illnesses, as well as prior surgery and trauma. Current medication, including over-the-counter drugs and phyto-

therapeutic agents, must be reviewed. A focused physical examination, including a digital rectal exam (DRE), is also mandatory. Urinalysis is required to rule out diagnoses other than BPH that may cause LUTS and may require additional diagnostic tests.^{1-3,5-7}

1.2. Recommended

Symptom inventory (should include bother assessment)

A formal symptom inventory (e.g., International Prostate Symptom Score [IPSS] or AUA Symptom Index [AUA-SI]) is recommended for an objective assessment of symptoms at initial consultation, for followup of symptom evolution for those on watchful waiting, and for evaluation of response to treatment.⁸⁻¹¹

Prostate-specific antigen

Testing of prostate-specific antigen (PSA) should be offered to patients who have at least a 10-year life expectancy and for whom knowledge of the presence of prostate cancer would change management, as well as those for whom PSA measurement may change the management of their voiding symptoms (i.e., estimate for prostate volume that may lead to more precise measurements). Among patients without prostate cancer, serum PSA may also be a useful surrogate marker of prostate size and may also predict risk of BPH progression.^{12,13}

1.3. Optional

In cases where the physician feels diagnostic uncertainty exists, it is reasonable to proceed with one or more of the following:

- Serum creatinine
- Urine cytology
- Uroflowmetry
- Postvoid residual (PVR)
- Voiding diary (recommend frequency volume chart for men with suspected nocturnal polyuria)
- Obstructive sleep apnea (OSA) screening for men with nocturia over the age of 50 (STOP BANG questionnaire)
- Sexual function questionnaire

1.4. Not recommended

The following diagnostic modalities are not recommended in the routine initial evaluation of a typical patient with BPH-associated LUTS. **These investigations may be required** in patients with another indication, such as hematuria, diagnostic uncertainty, DRE abnormalities, poor response to medical therapy, or for surgical planning:

- Cytology
- Cystoscopy

- Urodynamics
- Radiological evaluation of upper urinary tract
- Prostate ultrasound
- Prostate biopsy

An algorithm summarizing the appropriate diagnostic steps in the workup of a typical patient with MLUTS/BPH is summarized in Figure 1.

1.5. Further diagnostic considerations for surgery

Indications for surgery

Indications for MLUTS/BPH surgery¹⁻³ include 1) recurrent or refractory urinary retention; 2) recurrent urinary tract infections (UTIs); 3) bladder stones; 4) recurrent hematuria; 5) renal dysfunction secondary to BPH; 6) symptom deterioration despite medical therapy; and 7) patient preference. The presence of a bladder diverticulum is not an absolute indication for surgery unless associated with recurrent UTI or progressive bladder dysfunction.

Preoperative testing

Determination of prostate size and extent of median lobe are related to procedure-specific indications (see section on *Surgical Treatment*). For patients in whom surgery is being considered, cystoscopy should be performed to evaluate prostate size, as well as presence or absence of significant middle/median lobe and/or bladder calculi. Ultrasound (US) (either by transrectal ultrasound [TRUS] or transabdominal US) is recommended to determine the volume of the prostate and the extent of median lobe presence in order to select appropriate modality of surgical therapy. This information




Figure 1. Algorithm of appropriate diagnostic steps in the workup of a typical patient with male lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). PE: physical exam; PSA: prostate-specific antigen; PVR: postvoid residual; U/A: urinalysis.

can also be obtained from a recent abdominal computed tomography (CT) or magnetic resonance imaging (MRI).

2. Treatment guidelines

2.1 Principles of treatment

Therapeutic decision-making should be guided by the severity of the symptoms, the degree of bother, and patient preference. Information on the risks and benefits of BPH treatment options should be explained to all patients who are bothered enough to consider therapy. Patients should be invited to participate as much as possible using a shared decision-making approach to determine the best treatment selection for them. This can be facilitated with the use of the CUA surgical BPH decision aid.¹⁴ The patient's therapeutic goal of management should be discussed and documented.

Patients with mild symptoms (e.g., IPSS <7) should be counselled about a combination of lifestyle modification and watchful waiting. Patients with mild symptoms and severe bother should undergo further assessment.

Treatment options for patients with bothersome moderate (e.g., IPSS 8–18) and severe (e.g., IPSS 19–35) symptoms of BPH include watchful waiting/lifestyle modification, as well as medical, minimally invasive, or surgical therapies.

Physicians should use baseline age, LUTS severity, and prostate volume to advise patients of their individual risk of symptom progression, acute urinary retention (AUR) or future need for BPH-related surgery (these risk factors identify patients at risk for progression).

A variety of lifestyle changes may be suggested for patients with non-bothersome symptoms. These can include:

- Fluid restriction, particularly prior to bedtime
- Avoidance of caffeinated beverages, alcohol, and spicy foods
- Avoidance/monitoring of some drugs (e.g., diuretics, decongestants, antihistamines, antidepressants)
- Timed or organized voiding (bladder retraining)
- Avoidance or treatment of constipation
- Weight loss and prevention or treatment of conditions associated with metabolic syndrome
- Pelvic floor physical therapy (PFPT) in cases of suspected non-relaxing pelvic floor dysfunction (causing LUTS, pelvic and/or genital pain, bowel and sexual dysfunction, etc.) or overactive bladder and/or urinary incontinence (Kegel exercises, urge suppression, etc.)

2.2. Post-treatment followup

Watchful waiting

Patients on watchful waiting should have periodic physician-monitored visits to monitor for any complications associated

with their BPO. Physicians should assess either progression of bother, i.e., validated questionnaire such as IPSS (subjective) or worsening urinary function, i.e., uroflowmetry or PVR (objective).

Medical therapy

Patients started on medical therapy should have followup visit(s) to assess for efficacy and safety (side effects) of medications. If the patient-directed therapeutic goal is achieved, the patient may be followed by the primary care physician as part of a shared-care approach. The primary care physician should be counselled with clear instructions on followup and re-referral as necessary.

Surgical therapy

Patients who receive prostate surgery for BPH should be reviewed 4–6 weeks after catheter removal to evaluate treatment response (with symptom assessment [e.g., IPSS], and if indicated, uroflowmetry and PVR volume). Side effects and adverse events should also be screened for. The individual patient's circumstances and type of surgical procedure employed will determine the need for and type of further followup required by the urologist and/or primary care physician.

2.3 Medical therapy

The committee recommended few changes in the recommendations for the primary medical management of BPH and MLUTS with alpha-blockers and/or 5-alpha-reductase inhibitors (5ARIs) since 2018. Since the 2018 guideline publication, new evidence is available in regard to other medical therapy, namely beta-3 agonists, for the treatment of MLUTS.

2.3.1. Alpha-blockers

Alfuzosin, doxazosin, tamsulosin, terazosin, and silodosin are appropriate treatment options for LUTS secondary to BPH.¹²⁻²³ Doxazosin and terazosin require dose titration and blood pressure monitoring. Alpha-blockers do not alter the natural progression of BPH (little impact on prostate growth, risk of urinary retention, or the need for BPH-related surgery). The most common adverse effect associated with alpha-blockers is dizziness (2–10%, with the highest rates for terazosin and doxazosin), while ejaculatory disturbances are most often reported with tamsulosin and silodosin. Floppy iris syndrome has been reported in patients on alpha-blockers, particularly tamsulosin, but this does not appear to be an issue in men with no planned cataract surgery and can be managed by the ophthalmologist, who is aware that the patient is on the medication.²⁴ Although there are differences in the adverse event profiles of these agents, all five agents appear to have equal clinical effectiveness. The choice of agent should depend on the patient's comorbidities, side effect profile, and tolerance.

We recommend alpha-blockers as an excellent first-line therapeutic option for men with symptomatic bother due to BPH who desire treatment (*strong recommendation, evidence level A*).

2.3.2. 5-ARIs

Several studies have demonstrated that 5-ARI therapy, in addition to improving symptoms and causing a modest (25–30%) shrinkage of the prostate, can alter the natural history of BPH through a reduction in the risk of AUR and the need for surgical intervention.^{25,26} Efficacy is noted in patients with a prostate volume >30 cc (and/or PSA levels >1.5 ng/ml). 5-ARI treatment is associated with erectile dysfunction, decreased libido, ejaculation disorders, and rarely, gynecomastia and post-finasteride syndrome.²⁷

We recommend 5-ARIs (dutasteride and finasteride) as appropriate and effective treatment for patients with LUTS associated with demonstrable prostatic enlargement (*strong recommendation, evidence level A*).

2.3.3. Combination therapy (alpha-blocker and 5-ARI)

Prognostic factors suggesting the potential for BPH progression risk^{28,29} include: serum PSA >1.4 ng/mL, age >50 years, and gland volume >30 cc. Clinical trial results have shown that combination therapy significantly improves symptom score and peak urinary flow compared with either of the monotherapy options. Combination medical therapy is associated with decreased risk of urinary retention and/or prostate surgery, but also the additive side effects of dual therapy (in particular, ejaculatory disturbances).^{30,31}

We recommend the combination of an alpha-adrenergic receptor blocker and a 5-ARI as an appropriate and effective treatment strategy for patients with symptomatic LUTS associated with prostatic enlargement (>30 cc) (*strong recommendation, evidence level B*).

It may be appropriate to consider discontinuing the alpha-blockers in patients successfully managed with combination therapy after 6–9 months of combination therapy.^{32,33}

We suggest that patients successfully treated with combination therapy may be given the option of discontinuing the alpha-blocker. If symptoms recur, the alpha-blocker should be restarted (*conditional recommendation, evidence level B*).

2.3.4. Antimuscarinic and beta-3 agonist medications

Storage symptoms (urgency, frequency, nocturia) are a bothersome component of MLUTS associated with BPH. Antimuscarinics (anticholinergics) and the beta-3 agonists have demonstrated improvements in male storage LUTS (with and without BPH), including reductions in frequency,

urgency, and urgency incontinence episodes.^{34,35} Studies of contemporary antimuscarinics, such as tolterodine and fesoterodine, and the beta-3 agonist, mirabegron, have shown low rates of urinary retention, although caution should be exercised in elderly men and those with significant bladder outlet obstruction (BOO) (with PVR >250–300 cc since there is little evidence of safety in men with high PVRs).

We suggest that antimuscarinics or beta-3 agonists may be useful in predominately storage symptoms and BPH, and used with caution in those with significant BOO and/or an elevated PVR (*conditional recommendation, evidence level C*).

2.3.5. Antimuscarinic or beta-3 agonists in combination with alpha-blockers

Mixed LUTS (storage and voiding symptoms) can be managed safely with alpha-blockers in combination with antimuscarinics or beta-3-agonists. Clinical trials studied the following drug combinations: tamsulosin 0.4 mg plus solifenacin 5 mg, tamsulosin plus tolterodine ER 4 mg, and tamsulosin 0.4 mg plus mirabegron 50 mg.^{36–41} Evidence showed that combination therapies provide significant improvement in storage symptoms without clinical or statistical evidence of decreased maximum flow rate on uroflowmetry (Qmax) or increased risk of retention. Patients with high PVR >200 ml or previous history of AUR were excluded.

We suggest that an alpha-blocker combined with an antimuscarinic or beta-3 agonist may be useful to treat LUTS/BPH in men with both voiding and storage symptoms and failure of alpha-blocker monotherapy (*conditional recommendation, evidence level B*).

2.3.6. Phosphodiesterase inhibitors

PDE5Is have been shown to not only improve erectile function, but also are an effective treatment for male LUTS. Tadalafil 5 mg daily, due to its longer half-life, is approved for MLUTS. Studies have shown improvements in IPSS, storage and voiding symptoms, and quality of life.⁴² Evidence shows that combination therapy with PDE5I and alpha-blockers is superior to alpha-blockers alone in men with voiding symptoms and erectile dysfunction.⁴³

We recommend long-acting PDE5Is as monotherapy for men with LUTS/BPH, particularly in men with both LUTS and erectile dysfunction (*strong recommendation, evidence level B*).

2.3.7. Desmopressin

Nocturnal polyuria (NP) often coexists with MLUTS and BPH but may not respond to typical BPH pharmacotherapies. NP is a major contributing factor of nocturia and is defined by the International Continence Society (ICS) as an abnormally

large volume of urine during sleep. More specifically, 33% of the total daily urine volume occurs at night, while the daily total urine output remains normal. Desmopressin is a synthetic analogue of the antidiuretic hormone, arginine vasopressin (AVP). Desmopressin reduces total nocturnal voids and increases hours of undisturbed sleep by reducing urine production in men with NP.⁴⁴ While the risk of hyponatremia is low in men with normal baseline serum sodium, sodium must be checked at baseline in all men, as well as 4–8 days and 30 days after initiation of treatment in men taking desmopressin melts or men ≥ 65 years taking 50 μg oral disintegrating tablet. In men whose predominant symptom is bothersome nocturia and who do not respond to conservative measures or other monotherapies, desmopressin should be considered.

We recommend desmopressin as a therapeutic option in men with LUTS/BPH with nocturia as result of NP (*conditional recommendation, evidence level B*).

2.3.8. Phytotherapies

Plant-based herbal preparations may appeal to some patients. Common formulations include *Serenoa repens* (saw palmetto), *Pygeum africanum* (African plum bark), and *Urtica dioica* (stinging nettle). Phytotherapies lack consistent formulation, predictable pharmacokinetics, and regulatory oversight. Numerous studies and Cochrane meta-analyses report no significant difference between phytotherapies and placebo, as measured by AUA-SI, peak flow rates, prostate volume, residual urine volume, PSA, or quality of life.^{45–48} There are few side effects associated with phytotherapies but there are important potential drug interactions.

We do not recommend phytotherapies as standard treatment for MLUTS/BPH (*strong recommendation, evidence level B*).

2.4. Surgical therapy

2.4.1. TURP

Monopolar TURP

Monopolar TURP (M-TURP) remains the primary, standard-reference surgical treatment option for moderate-to-severe LUTS due to BPH in patients with prostate volume 30–80 cc.⁴⁹ Perioperative mortality has decreased over time and is currently approximately 0.1%, while morbidity is related to prostate volume (particularly >60 cc).⁵⁰ Contemporary series have reported the following complications: bleeding (2–9%), capsule perforation with significant extravasation (2%), TUR syndrome (0.8%), urinary retention (4.5–13%), infection (3–4%; sepsis 1.5%), incontinence ($<1\%$), bladder neck contracture (3–5%), retrograde ejaculation (65%),

erectile dysfunction (6.5%), and need for surgical retreatment (2%/year).^{51,52}

We recommend M-TURP as a standard first-line surgical therapy for men with moderate-to-severe LUTS/BPH with prostate volume of 30–80 cc (*strong recommendation, evidence level A*).

Bipolar TURP (including bipolar plasma kinetic vaporization)

Bipolar TURP (B-TURP) offers a resection alternative to M-TURP in men with moderate to-severe LUTS secondary to BPH with similar efficacy, but lower perioperative morbidity.^{52–54} The predominant difference between M-TURP and B-TURP is the decreased risk of perioperative bleeding and TUR syndrome. The choice of B-TURP should be based on equipment availability, surgeon experience, and patient preference.

We recommend B-TURP as a standard first-line surgical therapy for men with moderate-to-severe LUTS/BPH with prostate volume of 30–80 cc (*strong recommendation, evidence level B*).

2.4.2. Open simple prostatectomy

Open simple prostatectomy (OSP) is an effective treatment alternative for men with moderate-to-severe LUTS with substantially enlarged prostates >80 cc and who are significantly bothered by symptoms.⁵⁵ Other indications for OSP include plans for concurrent bladder procedure, such as diverticulectomy or cystolithotomy (for very large bladder calculi) and in men who are unable to be placed in dorsal lithotomy position due to severe hip disease.⁵⁶ OSP is the most invasive surgical method requiring longer hospitalization and catheterization. The estimated transfusion rate has been reported as 7–14%.^{55,56} Complications include transient urinary incontinence (8–10%), bladder neck contracture, and urethral stricture (5–6%).^{55,56}

We recommend OSP as a first-line surgical therapy when anatomic endoscopic enucleation of the prostate (AEEP) (see below) is unavailable for men with moderate-to-severe LUTS/BPH and enlarged prostate volume >80 cc (*strong recommendation, evidence level A*).

2.4.3. Minimally invasive simple prostatectomy

With the advent of minimally invasive surgery, starting with laparoscopy and proceeding to robotic-assisted laparoscopy, the natural evolution came to the OSP as well. These techniques are still relatively new.

Laparoscopic simple prostatectomy (LSP) and robot-assisted simple prostatectomy (RASP), like OSP, are indicated in patients with significantly enlarged prostates (>80 – 100 cc) and bothersome LUTS.^{57,58} They are also beneficial when

performed due to concomitant pathology, such as large bladder stones or bladder diverticulum. There are no randomized controlled trials comparing LSP and RASP to OSP or to any other enucleation procedure. The largest retrospective series includes both techniques and has shown both to be safe and effective.⁵⁹ A recent systematic review found that RASP showed similar improvements in IPSS, PVR, Qmax, and quality of life, while having similar complication rates and estimated blood loss (EBL) to laser vaporization and enucleation of the prostate.⁶⁰ In comparison to OSP, the length of stay (LOS) and EBL are significantly lower for RASP.⁶¹ Finally, catheterization time and LOS are longer with RASP compared to laser enucleation of the prostate.⁶⁰

We recommend LSP or RASP as alternative surgical therapies for men with moderate-to-severe LUTS/BPS and enlarged prostate volume >80 cc in centers where there are surgeons with high-level expertise in robotics or laparoscopy (conditional recommendation, evidence level B).

2.4.4. AEEP

AEEP adopts the principle of open prostatectomy (OP) using different energy sources and instruments. The holmium laser (HoLEP) with or without Moses technology, GreenLight laser (GreenLEP), monopolar enucleation (MonoleP), bipolar enucleation (BipoleP), diode laser (DiLEP), thulium laser (ThuLEP), and thulium fiber laser (ThuFLEP) are among the available energy sources. The efficacy and safety of AEEP, regardless of the energy source used, have been widely demonstrated.⁶²

When compared to TURP and OSP, AEEP was associated with greater improvements in IPSS, Qmax, and PVR. AEEP resulted in greater prostate tissue removal, reduced hemoglobin loss, shorter catheterization time, and shorter LOS.⁶³

Recent evidence supports the use of AEEP in patients with BPH on anticoagulant (AC) or antiplatelet (AP) therapy.⁶⁴⁻⁶⁶ AEEP has demonstrated durable results, with a low reoperation rate of 0–3.7% (attributed to adenoma regrowth) on long-term followup of up to 18 years.⁶⁷⁻⁷¹ The procedure requires a steep learning curve (estimated >20–50 cases).⁷²

We recommend AEEP as an alternative to TURP or OSP in men with moderate-to-severe LUTS and any size prostate >30 cc if performed by an AEEP-trained surgeon. AEEP can be safely performed in patients on AC/AP therapy (strong recommendation, evidence level A).

2.4.5. PVP

GreenLight-PVP (180W XPS and 120W HPS systems) provides comparable outcomes to TURP in terms of durable improvements in IPSS and Qmax, with similar overall complication rate.⁷³ Five-year mid-term durability of XPS reported a 1.1% retreatment rate in prostates with volumes of an average 80 g.⁷⁴

In the GOLIATH international, multicenter, randomized controlled trial comparing the 180W XPS PVP to TURP for prostate volumes 30–80cc, there was a statistically significant difference in early adverse events, notably bleeding-related one, within the first 30 days favoring XPS PVP.^{68,75} Compared to TURP, PVP has better perioperative safety, shorter catheterization time, and shorter hospitalization.⁷⁶ Multiple studies have demonstrated that PVP is safe and effective for elderly men, with significant medical comorbidities,⁷⁷ large median lobes,⁷⁸ and in patients who continue their AC/AP therapy, with negligible transfusion rates.⁷⁹⁻⁸¹ Further to GreenLight safety profile, PVP has been shown to be a cost-effective alternative to TURP in the Canadian setting.⁸² There exists no size or shape limitation to PVP; only surgeon expertise and clinical judgement dictate size limitations.

We recommend PVP as an alternative to M-TURP or B-TURP in men with moderate-to-severe LUTS (strong recommendation based on high-quality evidence). We also suggest GreenLight PVP therapy as an alternate surgical approach in men on anticoagulation or with a high cardiovascular risk (conditional recommendation, evidence level B).

2.4.6. Transurethral incision of the prostate

Transurethral incision of the prostate (TUIP) is an appropriate therapy for men with a small prostate size <30 cc without a middle lobe.⁸³ Symptoms and voiding parameters are improved and the risk of retrograde ejaculation and TUR syndrome is reduced (18.2% and 0%, respectively) compared to TURP; however, the risk of surgical retreatment for LUTS related to BPH are significantly higher for TUIP (18.4%) than after TURP (7.2%).

We recommend TUIP to treat moderate-to-severe LUTS in men with prostate volume <30 cc without a middle lobe. Patients should be made aware of the high retreatment rate (strong recommendation, evidence level B).

2.4.7. Minimally invasive techniques

Transurethral microwave therapy

Transurethral microwave therapy (TUMT) is an option for elderly patients with significant comorbidities or greater anesthesia risks, as this procedure can be performed under local anesthesia.^{84,85} Although short-term success for LUTS improvement has been reported, the long-term durability of TUMT is limited, with five-year cumulative retreatment rates from 42–59%.⁸⁶ TUMT should not be performed in patients with a significant median lobe.

We suggest TUMT therapy as a consideration for treatment of carefully selected, well-informed men (conditional recommendation, evidence level C).

Prostatic stents

Temporary stents can provide short-term relief from BPO in patients temporarily unfit for surgery.⁸⁷ In general, stents are subject to misplacement, migration, and poor tolerability because of exacerbation of LUTS and encrustation. Given these common side effects, prostatic stents have a limited role in the treatment of moderate-to-severe LUTS. A newer generation of stents are currently being evaluated and may provide an alternative surgical option for the management of BPH/LUTS in the future.

We suggest prostatic stents only as an alternative to catheterization in men unfit for surgery with a functional detrusor (*conditional recommendation, evidence level C*).

Prostatic urethral lift

The prostatic urethral lift procedure, or UroLift[®], (small, permanent, suture-based nitinol tabbed implants compress encroaching lateral lobes delivered under cystoscopic guidance), provides less effective but adequate and durable improvements in IPSS and QMax compared to TURP while preserving sexual function (no reported retrograde ejaculation observed at 12 months).⁸⁸ Most complications are mild and resolve within four weeks but include dysuria (34%), hematuria (26%), pelvic pain (19%), urge incontinence (7%), and UTI (3%). Surgical retreatment was 13.6% over five years.⁸⁹ A recent study (MedLift study) reported on the use of prostatic urethral lift in patients with a median lobe. For middle lobe deployment, the intravesical tissue is pulled into the prostatic fossa and affixed to either side of the urethra. Fort-four patients underwent this technique and results are very similar to the pivotal L.I.F.T. trial regarding improved IPSS and IPSS quality of life, while preserving ejaculatory function. It should be noted that followup for this study was only 12 months.⁹⁰

We suggest that prostatic urethral lift (UroLift) may be considered as an alternative treatment for men with LUTS interested in preserving ejaculatory function with prostates <80 cc. Prostatic urethral lift can also be offered to patients with a small-to-moderate median lobe and bothersome LUTS. Patients (with or without a median lobe) should be made aware of the higher retreatment rate at five years (*conditional recommendation, evidence level C*).

Convective water vapor energy ablation

Ablations using the Rezum[®] system (uses the thermodynamic principle of convective energy transfer) report significant improvement of IPSS and Qmax at three months and sustained until 12 months,⁹¹ with preservation of erectile and ejaculatory function.⁹² Recent five-year results have confirmed durability of the positive clinical outcomes, with a 57% reduction in IPSS, 45% increase in quality of life, and

44% increase in Qmax. Surgical retreatment rate is 4.4% at five years.⁹³

We suggest that the Rezum system of convective water vapor energy ablation may be considered an alternative treatment for men with LUTS interested in preserving ejaculatory function with prostates <80 cc, including those with a median lobe (*conditional recommendation, evidence level C*).

Image-guided robotic waterjet ablation

Aquablation (robotic-guided hydrodissection ablates prostatic parenchyma while sparing collagenous structures such as blood vessels and the surgical capsule)⁹⁴ has shown comparable improvements in efficacy and safety compared to TURP in men with <80 cc prostates.⁹⁵ Additional studies have also demonstrated efficacy and safety in glands 80–150 cc. Aquablation preserves erectile and ejaculatory function in nearly 100% and approximately 90% of patients, respectively. Five-year retreatment rates are low (6% at five years).

We suggest that Aquablation be offered to men with LUTS interested in preserving ejaculatory function with prostates <150 cc, with or without a middle lobe (*conditional recommendation, evidence level C*).

Temporary implantable nitinol device

Temporary implantable nitinol device (iTind) is a temporary (five days and then removed under local anesthetic), mechanical, stent-like device designed to remodel the bladder neck and the prostatic urethra through pressure necrosis.

Three prospective, randomized clinical trials (n=269) have demonstrated IPSS reduction of 45–60%, Qmax increase of 50–110%, no changes in erectile or ejaculatory function, and a retreatment rate of 9% at three years.^{96–98} Long-term durability studies are pending.

We recommend that iTind may be offered to men with LUTS interested in preserving ejaculatory function, with prostates 30-80 cc. Patients should be made aware of the higher retreatment rate at 3 years (*conditional recommendation, evidence level C*).

Prostatic artery embolization

Prostatic artery embolization (PAE) is a minimally invasive treatment option exclusively performed by interventional radiologists at specialized centers. PAE results in significant IPSS, Qmax, and PVR improvement compared to baseline at 12 months,⁹⁹ however, inferior outcomes compared to TURP^{100–102} or OSP.¹⁰³ Although PAE has reportedly fewer complications than TURP, non-targeted embolization may lead to rare ischemic complications like transient ischemic proctitis, bladder ischemia, urethral and ureteral stricture, or seminal vesicles ischemia.¹⁰⁴ Efficacy of PAE may be more advanta-

geous in prostate volumes >80 mL,¹⁰⁵ and can be considered as a treatment for gross hematuria of prostatic origin.¹⁰⁶

At centers with urological and radiological collaboration and technical expertise, highly selected, well-informed patients may be offered PAE if they wish to consider an alternative treatment option. Patients should be informed of lack of long-term durability (conditional recommendation, evidence level C).

Algorithms summarizing the management of a patient with MLUTS/BPH are summarized in Figures 2, 3.

2.5. Special situations

AUR

Data suggest that in patients with AUR, the use of alpha-blockers (specifically tamsulosin, alfuzosin, and silodosin) during the period of catheterization will increase the chances of successful voiding after catheter removal,^{107,108} while the addition of a 5-ARI may decrease the risk of future prostate surgery.^{30,31,109}

We suggest that men with AUR secondary to BPH may be offered alpha-blocker therapy during the period of catheterization (conditional recommendation, evidence level B).

Detrusor underactivity

There is no effective treatment for detrusor underactivity (DU), defined as a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span.¹¹⁰ In primary DU, treatment approach should be to facilitate bladder emptying, identify agents that can decrease bladder contractility, or increase urethral resistance. Behavioral modification, including scheduled voiding and or double voiding, clean intermittent self-catheterization (CIC), or indwelling catheters, are optional strategies.¹¹¹ The data suggests that DU is not necessarily a contraindication for TURP or enucleation.^{112,113}

We have no evidence-based specific recommendation for management of DU.

BPH-related bleeding

A complete assessment, including history and physical examination, urinalysis (routine microscopy, culture and sensitivity, cytology), upper tract radiological assessment, and cystoscopy, is necessary to exclude other sources of bleeding. Finasteride has been reported to reduce the risk of recurrent BPH-related hematuria.¹¹⁴




Figure 2. Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) management algorithm. ED: erectile dysfunction; PDE5: phosphodiesterase type 5; PSA: prostate-specific antigen.




Figure 3. Treatment algorithm of bothersome lower urinary tract symptoms (LUTS) refractory to conservative/medical treatment or in cases of absolute operation indications. The flowchart was stratified by the patient's ability to have anesthesia, cardiovascular risk, and prostate volume. *Current standard/first choice. The alternative treatments are presented in alphabetical order. **Must exclude the presence of a middle lobe. BPH: benign prostatic hyperplasia; B-TURP: bipolar transurethral resection of the prostate; HoLEP: holmium laser enucleation of the prostate; iTIND: temporary implantable nitinol device; M/TURP: monopolar transurethral resection of the prostate; PVP: photoselective vaporization of the prostate; TUIP: transurethral incision of the prostate; TUMT: transurethral microwave therapy.

We suggest that a trial with a 5-ARI is appropriate in men with BPH-related hematuria (conditional recommendation, evidence level C).

BPH patients with prostate cancer concern

The BPH patient with an elevated serum PSA and negative prostate biopsy may be counselled on the potential benefits of 5-ARI therapy (finasteride, dutasteride) for prostate cancer detection risk reduction.^{115,116} The patient must be aware of the possible low absolute increased risk (0.5–0.7%) in incidence of high-grade (Gleason 8–10) cancer with 5-ARI use. Most experts believe this phenomenon was observed due to an artifact of prostate glandular cytorreduction, induced by the 5-ARI, and it appears there is no demonstrable increase in prostate cancer mortality.¹¹⁷ Patients on 5-ARI therapy who experience a rising PSA 6–12 months after PSA nadir is reached should be assessed for the possibility of high-grade prostate cancer.¹¹⁸

We recommend case-to-case, patient-specific informed discussion and close PSA followup, as indicated, in men on 5-ARI therapy treatment for BPH (conditional recommendation, evidence level B).

Summary

MLUTS secondary to BPH remains one of the most common age-related disorders afflicting men. As the aging of the Canadian population continues, more men will be seeking advice and looking for guidance from their healthcare providers on the management of their symptoms. The information offered in this guideline document, based on consensus evaluation of the best available evidence, will aid Canadian urologists as they strive to provide state-of-the-art care to their patients.

Competing interests: Dr. Elterman has attended advisory boards for, is a speaker for, and has received grant funding from Allergan, Astellas, Boston Scientific, Ferring, Medtronic, and Pfizer; and has participated in clinical trials supported by Astellas, Medtronic, Meditate, and Procept Biorobotics. Dr. Aubé-Peterkin is an investigator for the Optilume trial supported by Urotronic. Dr. Elmansy has

received honoraria from Boston Scientific, Lumenis, and Clarion Medical Technologies. Dr. Zorn has received honoraria from Boston Scientific and as a proctor/lecturer for Greenlight; and participated in the WATER 2 supported by Procept BioRobotics. Dr. Bhajani is a consultant for Boston Scientific, Olympus, and Procept BioRobotics; and has participated in the WATER 2 trial supported by Procept BioRobotics. The remaining authors do not report any competing personal or financial interests related to this work

Prior to publication, this guideline update was reviewed by the CUA Guidelines Committee and the CUA Board of Directors.

References

- Nickel JC, Mendez-Probst CE, Whelan TF, et al. 2010 update: Guidelines for the management of benign prostatic hyperplasia. *Can Urol Assoc J* 2010;4:308-14. <https://doi.org/10.5489/cuaj.10124>
- McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association guideline: Management of benign prostatic hyperplasia (BPH). Published 2010; reviewed and validity confirmed 2014. Available at [http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(2010-reviewed-and-validity-confirmed-2014\)](http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)). Accessed Aug. 28, 2018.
- Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol* 2015;67:1099-1109. <https://doi.org/10.1016/j.eururo.2014.12.038>
- GRADE Guidelines 15. Available at <http://www.gradeworkinggroup.org/>. Accessed Aug. 28, 2018.
- Abrams P, Cardozo L, Wagg A, et al. Incontinence. 6th International Consultation on Incontinence, Tokyo, September 2016, ICUD, 6th edition 2017. <https://doi.org/10.1002/nau.23783>
- Nickel JC, Saad J. The American Urological Association 2003 guidelines on management of benign prostatic hyperplasia: A Canadian opinion. *Can J Urol* 2004;11:2186-93. <https://pubmed.ncbi.nlm.nih.gov/15182407/>
- Ramsey EW, Elhilali M, Goldenberg GS, et al for the Canadian Prostate Health Council. Practice patterns of Canadian urologists in benign prostatic hyperplasia and prostate cancer. *J Urol* 2000;163:499-502. [https://doi.org/10.1016/S0022-5347\(05\)67911-6](https://doi.org/10.1016/S0022-5347(05)67911-6)
- Cockett ATK, Aso Y, Denis L, et al. Recommendations of the International Consensus Committee concerning: 1. Prostate symptom score (IPSS) and quality of life assessment; 2. Diagnostic workup of patients presenting with symptoms suggestive of prostatism; 3. Patients evaluation for research studies; and 4. BPH treatment. In: Cockett ATK, Aso Y, Chatelain C, et al, eds. Proceedings of the first International Consultation on Benign Prostatic Hyperplasia. Paris: Scientific Communication 1991:279-340.
- Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. *J Urol* 1992;148:1549-57. [https://doi.org/10.1016/S0022-5347\(17\)36966-5](https://doi.org/10.1016/S0022-5347(17)36966-5)
- Robertson C, Link CL, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: The BACH and UREPIK studies. *BJU Int* 2007;99:347-54. <https://doi.org/10.1111/j.1464-410X.2007.06609.x>
- O'Leary MP, Wei JT, Roehrborn CG, et al. BPH registry and patient survey steering committee. Correlation of the international prostate symptom score bother question with the benign prostatic hyperplasia impact index in a clinical practice setting. *BJU Int* 2008;101:1531-5. <https://doi.org/10.1111/j.1464-410X.2008.07574.x>
- Levitt JM, Slawin KM. PSA and PSA derivatives as predictors of BPH progression. *Curr Urol Rep* 2007;8:269-74. <https://doi.org/10.1007/s11934-007-0072-y>
- Rendon RA, Mason RJ, Marzouk K, et al. Canadian Urological Association recommendations on prostate screening and early diagnosis. *Can Urol Assoc J* 2017;11:298-309. <https://doi.org/10.5489/cuaj.4888>
- Bouhadana D, Nguyen D-D, Raizenne B, et al. Evaluating the acceptability of an online patient decision aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Can Urol Assoc J* 2021;15:247-54. <https://doi.org/10.5489/cuaj.7492>
- Lukacs B, Grange JC, Comet D. One-year followup of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. *Urology* 2000;55:540-6. [https://doi.org/10.1016/S0090-4295\(99\)00539-7](https://doi.org/10.1016/S0090-4295(99)00539-7)
- Tsakamoto T, Masumori N, Rahman M, et al. Change in international prostate symptom score, prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. *Int J Urol* 2007;14:321-4. <https://doi.org/10.1111/j.1442-2042.2007.01596.x>
- Chapple CR. Alpha-adrenoreceptor antagonist in the year 2000: Is there anything new? *Curr Opin Urol* 2001;11:9-16. <https://doi.org/10.1097/00042307-200101000-00002>
- Marberger M, Harkawa R, de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. *Eur Urol* 2004;45:411-9. <https://doi.org/10.1016/j.eururo.2003.10.016>
- Bozlu M, Ulusoy E, Cayan S, et al. A comparison of four different alpha 1-blockers in benign prostatic hyperplasia patients with and without diabetes. *Scand J Urol Nephrol* 2004;38:391-5. <https://doi.org/10.1080/00365590410015678>
- Kirby RS. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. *BJU Int* 2003;91:41-4. <https://doi.org/10.1046/j.1464-410X.2003.03077.x>
- de Reijke TM, Klarskov P. Comparative efficacy of two alpha adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. *BJU Int* 2004;93:757-62. <https://doi.org/10.1111/j.1464-410X.2003.04720.x>
- Hutchison A, Farmer R, Verhamme K, et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. *Eur Urol* 2007;51:207-15. <https://doi.org/10.1016/j.eururo.2006.06.012>
- Wilt TJ, Howe RW, Rutks IR, et al. Terazosin for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2002:CD003851. <https://doi.org/10.1002/14651858.CD002081>
- Takmaz T, Can I. Clinical features, complications, and incidence of intraoperative floppy iris syndrome in patients taking tamsulosin. *Eur J Ophthalmol* 2007;17:909-13. <https://doi.org/10.1177/112067210701700607>
- McConnell JD, Bruskeiwitz R, Walsh P, et al and the PLESS Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. *N Engl J Med* 1998;338:557-63. <https://doi.org/10.1056/NEJM199802263380901>
- Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology* 2002;60:434-41. [https://doi.org/10.1016/S0090-4295\(02\)01905-2](https://doi.org/10.1016/S0090-4295(02)01905-2)
- Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. *JAMA Dermatol* 2021;157:35-42. <https://doi.org/10.1001/jamadermatol.2020.3385>
- Anderson JB, Roehrborn CG, Schalken JA, et al. The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk. *Eur Urol* 2001;39:390-9. <https://doi.org/10.1159/000052475>
- Marks L, Roehrborn C, Andriole G. Prevention of benign prostatic hyperplasia disease. *J Urol* 2006;176:1299-306. <https://doi.org/10.1016/j.juro.2006.06.022>
- McConnell JD, Roehrborn CG, Oliver OM, et al for the MTOPS Research Group. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med* 2003;349:2385-96. <https://doi.org/10.1056/NEJMoa030656>
- Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostate enlargement: Two-year results from the CombAT study. *J Urol* 2008;179:616-21. <https://doi.org/10.1016/j.juro.2007.09.084>
- Barkin J, Guimares M, Joacobi G, et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha reductase inhibitor dutasteride. *Eur Urol* 2003;44:461-6. [https://doi.org/10.1016/S0302-2838\(03\)00367-1](https://doi.org/10.1016/S0302-2838(03)00367-1)
- Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with BPH following cessation of alpha blockers. *Can Urol Assoc J* 2008;2:16-21. <https://doi.org/10.5489/cuaj.520>
- Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. *JAMA* 2006;296:2319-28. <https://doi.org/10.1001/jama.296.19.2319>
- Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: A critical analysis of five phase 3 studies. *Ther Adv Urol* 2017;10:9:137-54. <https://doi.org/10.1177/1756287217702797>
- Kaplan SA, Herschorn S, McVary KT, et al. Efficacy and safety of mirabegron vs. placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: A randomized, phase 4 study (PLUS). *J Urol* 2020;203:1163-71. <https://doi.org/10.1097/JU.0000000000000738>
- Chapple C, Herschorn S, Abrams P, et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. *Eur Urol* 2009;56:534-41. <https://doi.org/10.1016/j.eururo.2008.11.026>
- Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A randomized, placebo-controlled study (MATCH). *Eur Urol Focus* 2020;6:729-37. <https://doi.org/10.1016/j.euf.2019.10.019>

39. Kaplan SA, He W, Koltun WD, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: A randomized controlled trial. *Eur Urol* 2013;63:158-65. <https://doi.org/10.1016/j.eururo.2012.07.003>
40. Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE Study and NEPTUNE II open-label extension. *Eur Urol* 2015;67:262-70. <https://doi.org/10.1016/j.eururo.2014.07.013>
41. Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. *J Urol* 2015;193:921-6. <https://doi.org/10.1016/j.juro.2014.09.091>
42. Oelke M, Giuliano F, Miron V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomized, parallel, placebo-controlled clinical trial. *Eur Urol* 2012;61:917-25. <https://doi.org/10.1016/j.eururo.2012.01.013>
43. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α -blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. *Eur Urol* 2012;61:994-1003. <https://doi.org/10.1016/j.eururo.2012.02.033>
44. Weiss JP, Herschorn S, Albei CD, et al. Efficacy and safety of low-dose desmopressin orally disintegrating tablet in men with nocturia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. *J Urol* 2013;190:965-72. <https://doi.org/10.1016/j.juro.2012.12.112>
45. Habib FK, Wyllie MG. Not all brands are created equal: A comparison of selected components of different brands of Serenoa repens extract. *Prostate Cancer Prostatic Dis* 2004;7:195-200. <https://doi.org/10.1038/sj.pcan.4500746>
46. Barry MJ, Meleth S, Kreder KH, et al. Effect of increasing doses of saw palmetto on lower urinary tract symptoms: A randomized trial. *JAMA* 2011;306:1344-51. <https://doi.org/10.1001/jama.2011.1364>
47. Tacklind J, Macdonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2012;12:CD001423. <https://doi.org/10.1002/14651858.CD001423.pub3>
48. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. *Cochrane Database Syst Rev* 2002;1:CD001044. <https://doi.org/10.1002/14651858.CD001423>
49. Cornu JN, Ahyai S, Bachmann AJ, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: An update. *Eur Urol* 2015;67:1066-96. <https://doi.org/10.1016/j.eururo.2014.06.017>
50. Reich O, Gratzke C, Bockmann A, et al. Morbidity, mortality, and early outcome of transurethral resection of the prostate: A prospective, multicenter evaluation of 10 654 patients. *J Urol* 2008;180:246-9. <https://doi.org/10.1016/j.juro.2008.03.058>
51. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. *Eur Urol* 2010;58:384-97. <https://doi.org/10.1016/j.eururo.2010.06.005>
52. Mamoulakis C, Sofras F, de la Rosette J, et al. Bipolar vs. monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. *Cochrane Database Syst Rev* 2014;1:CD009629. <https://doi.org/10.1002/14651858.CD009629.pub3>
53. Geavlete B, Georgescu D, Mulescu R, et al. Bipolar plasma vaporization vs. monopolar and bipolar TURP: A prospective, randomized, long-term comparison. *Urology* 2011;78:930-5. <https://doi.org/10.1016/j.urology.2011.03.072>
54. Muslumanoglu AY, Yuruk E, Binbay M, et al. Transurethral resection of prostate with plasmakinetic energy: 100 months results of a prospective, randomized trial. *BJU Int* 2012;110:546-9. <https://doi.org/10.1111/j.1464-410X.2011.10770.x>
55. Varkarakis I, Kyriakakis Z, Delis A, et al. Long-term results of open transvesical prostatectomy from a contemporary series of patients. *Urology* 2004;64:306-10. <https://doi.org/10.1016/j.urology.2004.03.033>
56. Lin, Y, Wu X, Xu A, et al. Transurethral enucleation of the prostate vs. transvesical open prostatectomy for large benign prostatic hyperplasia: A systematic review and meta-analysis of randomized controlled trials. *World J Urol* 2016;34:1207-19. <https://doi.org/10.1007/s00345-015-1735-9>
57. Naspro R, Gomez Sancha F, Manica M, et al. From "gold standard" resection to reproducible "future standard" endoscopic enucleation of the prostate: What we know about anatomical enucleation. *Minerva Urol Nefrol* 2017;69:446-58. <https://doi.org/10.23736/S0393-2249.17.02834-X>
58. Nestler S, Bach T, Herrmann T, et al. Surgical treatment of large volume prostates: A matched pair analysis comparing the open, endoscopic (ThuVep) and robotic approach. *World J Urol* 2019;37:1927-31. <https://doi.org/10.1007/s00345-018-2585-z>
59. Autorino R, Zarger H, Mariano MB, et al. Perioperative outcomes of robotic and laparoscopic simple prostatectomy: A European-American multi-institutional analysis. *Eur Urol* 2015;68:86-94. <https://doi.org/10.1016/j.eururo.2014.11.044>
60. Kordan Y, Canda AE, Koseoglu E, et al. Robotic-assisted simple prostatectomy: A systematic review. *J Clin Med* 2020;9:1798. <https://doi.org/10.3390/jcm9061798>
61. Scarcella S, Castellani D, Gauhar V, et al. Robotic-assisted vs. open simple prostatectomy: Results from a systematic review and meta-analysis of comparative studies. *Invest Clin Urol* 2021;62:631-40. <https://doi.org/10.4111/icu.20210297>
62. Herrmann TR. Enucleation is enucleation is enucleation is enucleation. *World J Urol* 2016;34:1353-5. <https://doi.org/10.1007/s00345-016-1922-3>
63. Chen CH, Chung CH, Chu HC, et al. Surgical outcome of anatomical endoscopic enucleation of the prostate: A systemic review and meta-analysis. *Andrologia* 2020;52:e13612. <https://doi.org/10.1111/and.13612>
64. El Tayeb MM, Jacob JM, Bhojani N, et al. Holmium laser enucleation of the prostate in patients requiring anticoagulation. *J Endourol* 2016;30:805-9. <https://doi.org/10.1089/end.2016.0070>
65. Rivera M, Krambeck A, Lingeman J. Holmium laser enucleation of the prostate in patients requiring anticoagulation. *Curr Urol Rep* 2017;18:77. <https://doi.org/10.1007/s11934-017-0746-z>
66. Romero-Otero J, García-González L, García-Gómez B, et al. Factors influencing intraoperative blood loss in patients undergoing holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia: A large, multicenter analysis. *Urology* 2019;132:177-82. <https://doi.org/10.1016/j.urology.2019.06.024>
67. Ibrahim A, Alharbi M, Elhilali MM, et al. 18 years of holmium laser enucleation of the prostate: A single-center experience. *J Urol* 2019;202:795-800. <https://doi.org/10.1097/JU.000000000000280>
68. Gilling PJ, Wilson LC, King CJ, et al. Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: Results at 7 years. *BJU Int* 2012;109:408-11. <https://doi.org/10.1111/j.1464-410X.2011.10359.x>
69. Zhu L, Chen S, Yang S, et al. Electrosurgical enucleation vs. bipolar transurethral resection for prostates larger than 70 ml: A prospective, randomized trial with 5-year followup. *J Urol* 2013;189:1427-31. <https://doi.org/10.1016/j.juro.2012.10.117>
70. Elshal AM, Soltan M, El-Tabey NA, et al. Randomized trial of bipolar resection vs. holmium laser enucleation vs. Greenlight laser vaporization of the prostate for treatment of large benign prostate obstruction: 3-year outcomes. *BJU Int* 2020;126:731-8. <https://doi.org/10.1111/bju.15161>
71. Świniarski PP, Stępień S, Dudzić W, et al. Thulium laser enucleation of the prostate (TmLEP) vs. transurethral resection of the prostate (TURP): Evaluation of early results. *Cent European J Urol* 2012;65:130-4. <https://doi.org/10.5173/cej.2012.03.art6>
72. Elzayat EA, Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): Long-term results, reoperation rate, and possible impact of the learning curve. *Eur Urol* 2007;52:1465-72. <https://doi.org/10.1016/j.eururo.2007.04.074>
73. Thomas JA, Tubaro A, Barber N, et al. A multicenter, randomized, non-inferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: Two-year outcomes of the GOLIATH study. *Eur Urol* 2016;69:94-102. <https://doi.org/10.1016/j.eururo.2015.07.054>
74. Ajib K, Mansoura M, Zanaty M, et al. Photoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes. *Can Urol Assoc J* 2018;12:E318-24. <https://doi.org/10.5489/auaj.4895>
75. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporization vs. transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European multicenter, randomized trial — the GOLIATH study. *Eur Urol* 2014;65:931. <https://doi.org/10.1016/j.eururo.2013.10.040>
76. Bachmann A, Schurch L, Ruszat R, et al. Photoselective vaporization (PVP) vs. transurethral resection of the prostate (TURP): A prospective bicenter study of perioperative morbidity and early functional outcome. *Eur Urol* 2005;48:965-71. <https://doi.org/10.1016/j.eururo.2005.07.001>
77. Rajih E, Tholomier C, Hueber PA, et al. Evaluation of surgical outcomes with Photoselective GreenLight XPS laser vaporization of the prostate in high medical risk men with benign prostatic enlargement: A multicenter study. *J Endourol* 2017;31:686-93. <https://doi.org/10.1089/end.2016.0782>
78. Nguyen DD, Sadri I, Law K, et al. Impact of the presence of a median lobe on functional outcomes of greenlight photovaporization of the prostate (PVP): An analysis of the Global Greenlight Group (GGG) Database. *World J Urol* 2021;39:3881-9. <https://doi.org/10.1007/s00345-020-03529-w>
79. Lee DJ, Rieken M, Halpern J, et al. Laser vaporization of the prostate with the 180-W XPS-Greenlight laser in patients with ongoing platelet aggregation inhibition and oral anticoagulation. *Urology* 2016;91:167. <https://doi.org/10.1016/j.urology.2016.01.021>
80. Meskawi M, Hueber PA, Valdivieso R, et al. Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532 nm laser photovaporization Greenlight XPS-180 W for benign prostate hyperplasia. *World J Urol* 2019;37:1671-8. <https://doi.org/10.1007/s00345-018-2560-8>

81. Ruszat R, Wyler S, Forster T et al. Safety and effectiveness of photoselective vaporization on of the prostate (PVP) in patients on ongoing oral anticoagulation. *Eur Urol* 2007;51:1031. <https://doi.org/10.1016/j.euro.2006.08.006>
82. Bowen JM, Whelan JP, Hopkins RB, et al. Photoselective vaporization for the treatment of benign prostatic hyperplasia. *Ont Health Technol Assess Ser* 2013;13:1-34.
83. Lourenco T, Shaw M, Fraser C, et al. The clinical effectiveness of transurethral incision of the prostate: A systematic review of randomized controlled trials. *World J Urol* 2010;28:23-32. <https://doi.org/10.1007/s00345-009-0496-8>
84. de la Rosette J, Laguna MP, Gravas S, et al. Transurethral microwave thermotherapy: The gold standard for minimally invasive therapies for patients with benign prostatic hyperplasia? *J Endourol* 2003;17:245-51. <https://doi.org/10.1089/089277903765444393>
85. D'Ancona FC, van der Bij AK, Francisa EA, et al. Results of high-energy transurethral microwave thermotherapy in patients categorized according to the American Society of Anesthesiologists operative risk classification. *Urology* 1999;53:322-8. [https://doi.org/10.1016/S0090-4295\(98\)00502-0](https://doi.org/10.1016/S0090-4295(98)00502-0)
86. Gravas S, Laguna P, Kiemenen LA, et al. Durability of 30-minute high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: A study of 213 patients with and without urinary retention. *Urology* 2007;69:854-8. <https://doi.org/10.1016/j.urology.2007.01.070>
87. Vanderbrink BA, Rastinehad AR, Badlani G. Prostatic stents for the treatment of benign prostatic hyperplasia. *Curr Opin Urol* 2007;17:1-6. <https://doi.org/10.1097/MOU.0b013e3280117747>
88. Senksen J, Barber NJ, Speakman, MJ et al. Prospective, randomized, multinational study of prostatic urethral lift vs. transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol* 2015;68:643-52. <https://doi.org/10.1016/j.euro.2015.04.024>
89. Roehrborn CG, Barkin J, Gange SN, et al. Five-year results of the prospective, randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol* 2017;24:8802-13.
90. Rukstalis D, Grier D, Stroup SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. *Prostate Cancer Prostatic Dis* 2019;22:411-9. <https://doi.org/10.1038/s41391-018-0118-x>
91. McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: A multicenter, randomized controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol* 2016;195:1529-38. <https://doi.org/10.1016/j.juro.2015.10.181>
92. McVary KT, Gange SN, Gittelman MC, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Randomized controlled study. *J Sex Med* 2016;13:924-33. <https://doi.org/10.1016/j.jsxm.2016.03.372>
93. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter, randomized, sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol* 2021;206:715-24. <https://doi.org/10.1097/JU.0000000000001778>
94. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: One-year results. *J Urol* 2017;197:1565-72. <https://doi.org/10.1016/j.juro.2017.01.056>
95. Gilling P, Barner N, Bidair M, et al. WATER: A double-blind, randomized controlled trial of aquablation vs. transurethral resection of the prostate in benign prostatic hyperplasia. *J Urol* 2018;199:1252-61. <https://doi.org/10.1016/j.juro.2017.12.065>
96. Amparore D, Fiori C, Valerio M, et al. 3-year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. *Prostate Cancer Prostatic Dis* 2021;24:349-57. <https://doi.org/10.1038/s41391-020-00281-5>
97. Chughtai B, Elterman D, Shore N, et al. The TiInd temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, controlled trial. *Urology* 2020;153:270-6. <https://doi.org/10.1016/j.urology.2020.12.022>
98. De Nunzio C, Cantiello F, Fiori C, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (TiInd) in men with LUTS: 6-month interim results of the MT-06 study. *World J Urol* 2021;39:2037-42. <https://doi.org/10.1007/s00345-020-03418-2>
99. Pisco JM, Rio Tinto H, et al. Embolization of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: Results of short- and mid-term followup. *Eur Radiol* 2013;23:2561-72. <https://doi.org/10.1007/s00330-012-2714-9>
100. Carnevale FC, Iscaife A, Yoshinaga EM, et al. Transurethral resection of the prostate (TURP) vs. original and PerFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (bph): Preliminary results of a single-center, prospective, urodynamic-controlled analysis. *Cardiovasc Intervent Radiol* 2016;39:44-52. <https://doi.org/10.1007/s00270-015-1202-4>
101. Gao YA, Huang Y, Zhang R, et al. Benign prostatic hyperplasia: Prostatic arterial embolization vs. transurethral resection of the prostate — a prospective, randomized, and controlled clinical trial. *Radiology* 2014;270:920-8. <https://doi.org/10.1148/radiol.13122803>
102. Shim SR, Kanhai KJ, Ko YM, et al. Efficacy and safety of prostatic arterial embolization: Systematic review with meta-analysis and meta-regression. *J Urol* 2017;197:465-79. <https://doi.org/10.1016/j.juro.2016.08.100>
103. Russo GI, Kurbatov D, Sansalone S, et al. Prostatic arterial embolization vs. open prostatectomy: A one-year matched-pair analysis of functional outcomes and morbidities. *Urology* 2015;86:343-8. <https://doi.org/10.1016/j.urology.2015.04.037>
104. Abt D, Hechelhammer L, Müllhaupt G, et al. Comparison of prostatic artery embolisation (PAE) vs. transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomized, open label, non-inferiority trial. *BMJ* 2018;361:k2338. <https://doi.org/10.1136/bmj.k2338>
105. Bhatia S, Sinha VK, Harward S, et al. Prostate artery embolization in patients with prostate volumes of 80 ml or more: A single-institution retrospective experience of 93 patients. *J Vasc Interv Radiol* 2018;29:1392-8. <https://doi.org/10.1016/j.jvir.2018.05.012>
106. Kably I, Acharya V, Richardson AJ, et al. Prostatic artery embolization in refractory hematuria of prostatic origin. *Tech Vasc Interv Radiol* 2020;23:100694. <https://doi.org/10.1016/j.tvir.2020.100694>
107. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. *BJU Int* 2005;95:354-7. <https://doi.org/10.1111/j.1464-410X.2005.05299.x>
108. McNeill SA, Hargreave TB, Roehrborn CG. Alfuzosin 10 mg once daily in the management of acute urinary retention: Results of a double-blind, placebo-controlled study. *Urology* 2005;65:83-9. <https://doi.org/10.1016/j.urology.2004.07.042>
109. Patel SB, Ranka K, Kundargi VS, et al. Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter: A prospective, randomized study. *Cent European J Urol* 2017;70:259-63. <https://doi.org/10.5173/cej.2017.1313>
110. Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-committee of the International Continence Society. *NeuroUrol Urodyn* 2002;21:167-78. <https://doi.org/10.1002/nau.10052>
111. Chapple CR, Osman NI, Birder L, et al. The underactive bladder: A new clinical concept? *Eur Urol* 2015;68:351-3. <https://doi.org/10.1016/j.euro.2015.02.030>
112. Potts B, Belsante M, Peterson A, et al. Bladder outlet procedures are an effective treatment for patients with urodynamically confirmed detrusor underactivity without bladder outlet obstruction. *J Urol* 2016;195:e975. <https://doi.org/10.1016/j.juro.2016.02.1712>
113. Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. *Urology* 2016;97:208-11. <https://doi.org/10.1016/j.urology.2016.07.010>
114. Delakas D, Lianos E, Karyotis I, et al. Finasteride: A long-term followup in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. *Urol Int* 2001;67:69-72. <https://doi.org/10.1159/000050948>
115. Thompson IN, Goodman PJ, Tangen CM, et al. The influence of finasteride in the development of prostate cancer. *N Engl J Med* 2003;349:211-20. <https://doi.org/10.1056/NEJMoa030660>
116. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* 2010;362:1192-202. <https://doi.org/10.1056/NEJMoa0908127>
117. Grubb RL, Andriole G, Sommerville MC, et al. The REDUCE followup study: Low rate of new prostate cancer diagnosis observed during a two-year, observational followup study of men who participated in the REDUCE trial. *J Urol* 2013;189:871-977. <https://doi.org/10.1016/j.juro.2012.09.099>
118. Klotz L, Chetner M, Chin J, et al. Canadian consensus conference: The FDA decision on the use of 5ARIs. *Can Urol Assoc J* 2012;6:83-8. <https://doi.org/10.5489/auaj.12058>

Correspondence: Dr. Dean Elterman, Division of Urology, University of Toronto, Toronto, ON, Canada; Dean.Elterman@uhn.ca